Smoking-related intersticial fibrosis (srif): A new entity?

E. De Freitas Gonzalez (León, Spain), J. Villegas Alcázar (León, Spain), R. Almeida Cabrera (León, Spain), C. Mier Bango (León, Spain), L. Sierra Herranz (León, Spain), J. Juan García (León, Spain), I. Herráez Ortega (León, Spain), N. Alonso Orcajo (León, Spain), S. García García (León, Spain), E. Bollo De Miguel (León, Spain)

Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs)
Disease area: Interstitial lung diseases

Congress or journal article abstract

Abstract

INTRODUCTION:SRIF was described as changes in lung parenchyma (hyalinized interstitial fibrosis, alveolar septal thickening, emphysema and respiratory bronchiolitis-RB) in lobectomy specimens from smokers with cancer and eventually by HRCT (ground-glass attenuation, reticulation and thick-walled cysts without traction bronchiectasis or parenchymal distortion)

OBJECTIVES:To describe a group of SRIF patients as associated with interstitial lung disease (ILD) and/or emphysema

METHODS:Retrospective study on SRIF patients diagnosed in ILD consult since 2016 by HRCT. The variables included:age, sex, smoking habit, HRCT findings, spirometry, DLCO, pulmonary biopsy and diagnosis

RESULTS:30 patients (28 ?,2 ?); mean age 69; 80% ex-smokers, 20% current smokers. All underwent HRTC with findings of SRIF and another ILD in most cases (Table 1). Spirometry pattern was obstructive in 11, non-obstructive in 3 and normal in 14. DLCO was low in 26 (mild 9, moderate 13, severe 4). Out of 4 pulmonary biopsies (1 transbronchial and 3 surgical) SRIF was found in the surgical ones. Final diagnoses: ILD 19 (Table 2), COPD and/or emphysema 17. In 17 patients SRIF was associated with other smoking related-ILD:9 CPFE, 5 RB-ILD, 2 pulmonary LCH, 1 RA-ILD. 21 patients were evaluated in ILD multidisciplinary meeting

CONCLUSIONS:1-Radiologists must consider SRIF on performing HRCT on smokers or ex-smokers. 2-SRIF may coexist with multiple HRCT patterns of smoking-related ILD 

TABLE 1-HRTC PATTERN Patients
UIP  5
Possible UIP 1
Inconsistent UIP 3
NSIP 3
RB-ILD 5
Pulmonary LCH 2

TABLE 2-ILD diagnosis Patients
CPFE (RA-ILD) 1
CPFE (IPF) 5
CPFE (NSIP) 1
CPFE (HP) 1
CPFE (Unclassifiable IIP) 1
IPAF 2
RB-ILD 5
Unclassifiable IIP 1
Pneumoconiosis 1
RA-ILD 1



Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
E. De Freitas Gonzalez (León, Spain), J. Villegas Alcázar (León, Spain), R. Almeida Cabrera (León, Spain), C. Mier Bango (León, Spain), L. Sierra Herranz (León, Spain), J. Juan García (León, Spain), I. Herráez Ortega (León, Spain), N. Alonso Orcajo (León, Spain), S. García García (León, Spain), E. Bollo De Miguel (León, Spain). Smoking-related intersticial fibrosis (srif): A new entity?. 3031

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Combined emphysema & interstitial pulmonary disease. A new disease entity?
Source: Eur Respir J 2002; 20: Suppl. 38, 587s
Year: 2002

Combined pulmonary fibrosis and emphysema: A distinct entity?
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012

Lung fibrosis. An entity unto itself?
Source: ERS Research Seminar 2016
Year: 2016

Cystic interstitial lung disease - a rare disease?
Source: International Congress 2015 – CC4 Diagnosis of cystic interstitial lung disease
Year: 2015

Smoking-related interstitial lung diseases: a concise review
Source: Eur Respir J 2001; 17: 122-132
Year: 2001



Connective tissue disease-associated interstitial lung diseases and interstitial pneumonia with autoimmune features: different entities?
Source: Virtual Congress 2020 – Diagnostic and prognostic markers for disease-associated interstitial lung disease and hypersensitivity pneumonitis
Year: 2020


Idiopathic non-specific interstitial pneumonia (NSIP): is it an autoimmune clinical entity?
Source: Annual Congress 2007 - Miscellaneous interstitial lung diseases related to systemic and other diseases
Year: 2007


Pirfenidone in idiopathic pulmonary fibrosis - Real life experience from a german tertiary referral centre for interstitial lung diseases
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013

Diffuse dendriform pulmonary ossification in a usual interstitial pneumonia-like distribution: A distinct entity or a variant of idiopathic pulmonary fibrosis?
Source: International Congress 2014 – ILDs 1
Year: 2014


Does emphysema coexistence with IPF change prognosis?
Source: International Congress 2015 – IPF: clinical aspects
Year: 2015

Relevance of the expert ILD clinical-radiological evaluation of referred cases to the MDT
Source: International Congress 2016 – Clinical aspects of ILD
Year: 2016


Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms?
Source: Eur Respir J 2007; 30: 835-839
Year: 2007



Lung inflammation in cystic fibrosis: an overlooked therapeutic target?
Source: Virtual Congress 2020 – Cystic fibrosis: from cradle to old age
Year: 2020


Idiopathic pulmonary fibrosis: a treatable disease?
Source: Eur Respir J 2003 Dec 01;22(6):872-873
Year: 2003


Fibulin-1 is a novel biomarker of disease severity in pulmonary fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013

Idiopathic non-specific interstitial pneumonia (iNSIP): do the patients develop connective tissue disease (CTD) during follow-up?
Source: International Congress 2016 – Connective tissue disorders
Year: 2016

Idiopathic interstitial pneumonias - where is inflammation of relevance?
Source: Research Seminar 2004 - Genotyping and Phenotyping of Diffuse Parenchymal Lung Diseases
Year: 2004


What’s new in interstitial lung diseases in children?
Source: Virtual Congress 2021 – Paediatric year in review
Year: 2021